GlaxoSmithKline: Purpura, Thrombocytopenic, Idiopathic trials
The registry lists 11 Purpura, Thrombocytopenic, Idiopathic studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 2Phase 2 4Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.CompletedNCT01520909Phase 3Results posted
- Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00908037Phase 2Results posted
- Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00828750Phase 3Results posted
- Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00540423Phase 3Results posted
- Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)CompletedNCT00424177Phase 2Results posted
- RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With EltrombopagCompletedNCT00370331Phase 3Results posted
- Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy SubjectsCompletedNCT02281370Phase 1
- Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and RomiplostimCompletedNCT01439321
- Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment ContinuationCompletedNCT00621894Phase 2
- Eltrombopag Taste Testing in Healthy Adult VolunteersCompletedNCT00487968Phase 1
- SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)CompletedNCT00102739Phase 2